Summary: In a post-hoc analysis of a randomised trial in alcohol use disorder, 26 weeks of weekly exenatide did not change pro-inflammatory or metabolic biomarkers compared with placebo, despite people with the disorder showing higher inflammation than controls at baseline.
PICO Summary
| Element | Detail |
|---|---|
| Population | 124 individuals with alcohol use disorder (plus 23 without, for baseline comparison); Denmark. |
| Intervention | Once-weekly exenatide for 26 weeks (n=40); 25 inflammatory and metabolic biomarkers measured. |
| Comparison | Placebo (n=37). |
| Outcome | At baseline, those with alcohol use disorder had higher IL-6 (1.56 vs 0.62 pg/mL), hsCRP (3.30 vs 1.34 mg/L), and FGF-21, and lower GIP. After treatment, no significant change in any biomarker with exenatide versus placebo. |
Expert Commentary
This is a negative biomarker analysis, and a useful one. The hypothesis was reasonable, since GLP-1 agonists reliably lower inflammatory markers in diabetes and obesity, so one might expect the same in alcohol use disorder, which is also an inflammatory state. The result that they did not is informative precisely because it suggests disease context matters: the inflammation of alcohol use disorder, driven by gut permeability, endotoxaemia, direct toxicity, and nutritional deficiency, may simply not be the same target as metabolic-syndrome inflammation, so a drug that addresses one does not automatically touch the other. Two honest caveats: this is a post-hoc analysis rather than a prespecified endpoint, and the real clinical question for this field, whether GLP-1 agonists reduce drinking, sits in the parent trial, not here. Reassuringly, the drug was well tolerated in a population with potential hepatic and pancreatic vulnerability. Can I use this with my patients? Yes, as a boundary on expectations. It tells me not to expect anti-inflammatory benefit from a GLP-1 agonist in alcohol use disorder, while the established route to lowering that inflammation, reducing alcohol intake and repleting nutrition, remains the priority.
References
Hviid MEB, Christoffersen LAN, Klausen MK, et al. Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: post hoc results from a randomized, double-blinded, placebo-controlled clinical trial. Alcohol Clin Exp Res (Hoboken). 2025;49(8):1659–1666. doi:10.1111/acer.70110